DEFA14A ·Filed Apr 28, 2026

ERAS

Erasca, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed5mo ago SEC0001193125-26-187382
Proxy solicitation materials
Actionable Insight • Neutral

Routine annual meeting proxy — no contested items or activist involvement. Monitor for any late-breaking shareholder proposals or dissident activity ahead of the June 26 meeting, but no immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
ERAS ▲ +109.77% at T+60d
NEUTRAL call ✓ call won +109.77% · α vs SPY +105.66% · entry $9.11 → $19.11
Entry anchored
Apr 28, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α -1.02%
$9.11
settled 5mo ago
T+5d
+9.66%
call +9.66% · α +6.55%
$9.99
settled 5mo ago
T+20d
+36.88%
call +36.88% · α +31.42%
$12.47
settled 4mo ago
T+60d
+109.77%
call +109.77% · α +105.66%
$19.11
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Erasca filed definitive additional proxy materials (DEFA14A) for its June 26, 2026 Annual Meeting. The board recommends voting FOR the election of three Class II directors (Alexander W. Casdin, Julie Hambleton, M.D., Michael D. Varney, Ph.D.) and FOR the ratification of KPMG LLP as independent auditor for FY2026. This is a routine annual meeting solicitation with no contested matters or activist demands disclosed.

Key Facts

  • Annual Meeting scheduled for June 26, 2026 at 11:30 AM PT, held virtually via www.proxydocs.com/ERAS
  • Record date for stockholders: April 27, 2026
  • Proposal 1: Elect three Class II directors for three-year terms expiring at 2029 Annual Meeting
  • Director nominees: Alexander W. Casdin, Julie Hambleton M.D., Michael D. Varney Ph.D.
  • Proposal 2: Ratify appointment of KPMG LLP as independent registered public accounting firm for FY2026
  • Board recommends FOR votes on Proposals 1 and 2
  • Proposal 3: Transact other business as may properly come before the meeting
  • Paper copy request deadline: June 15, 2026

Financial Impact

No financial impact — routine proxy solicitation with no material financial disclosures

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-187382
Document: 0001193125-26-187382-index-headers.html0001193125-26-187382
Document: 0001193125-26-187382-index.html0001193125-26-187382
Document: 0001193125-26-187382.txt0001193125-26-187382
21 reports for ERAS
Performance horizon
89% Hit rate 8 of 9 directional calls best @ T+60▲ +95.35%Apr 27, 2026
Filters
Rows
Reports for ERAS — sortable, filterable
TypeNow
Aug 24, 2026
5w ago
8-K
BULLISH ★ 5/10
$17.60 $15.55▼ −11.65%▼ −12.96%$14.94 (−15.09%)
Aug 17, 2026
6w ago
144
NEUTRAL ★ 3/10
$18.28 $16.16▼ −11.60%▼ −10.07%$14.94 (−18.24%)
Aug 13, 2026
7w ago
Institutional Cluster
BULLISH ★ 6/10
$17.86 $15.88▼ −11.09%▼ −9.34%$14.94 (−16.32%)
Aug 12, 2026
7w ago
3
NEUTRAL ★ 2/10
$17.86 $15.88▼ −11.09%▼ −9.34%$14.94 (−16.32%)
Aug 11, 2026
7w ago
Press Release
NEUTRAL ★ 5/10
$18.58 $16.03▼ −13.72%▼ −11.83%$14.94 (−19.56%)
Jul 22, 2026
10w ago
Press Release
BEARISH ★ 6/10
$19.51 $18.07▲ +7.38%▲ +10.28%$14.94 (+23.40%)
Jul 14, 2026
11w ago
8-K
MIXED ★ 6/10
$21.26 $18.58▼ −12.61%▼ −14.95%$14.94 (−29.70%)
Jul 14, 2026
11w ago
424B5
MIXED ★ 6/10
$21.26 $18.58▼ −12.61%▼ −14.95%$14.94 (−29.70%)
Jul 14, 2026
11w ago
Press Release
BEARISH ★ 7/10
$19.50 $18.31▲ +6.10%▲ +8.59%$14.94 (+23.36%)
Jul 13, 2026
11w ago
Press Release
BULLISH ★ 7/10
$19.50 $18.31▼ −6.10%▼ −8.59%$14.94 (−23.36%)
Showing 10 of 21

US Market Status

Market Open — Closes in 3h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access